Atomoxetine-induced myocardial infarction

Ali Seifi, Heidi Griffith, Sahar Avestimehr, Haitham Dib

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Atomoxetine (Strattera®, Eli Lilly and Co.) is the first non-stimulant drug in the United States (US) to be approved for the treatment of attention deficit hyperactivity disorder (ADHD). In the past, physicians have been concerned about the safety of a variety of ADHD medications. As a result, non-stimulant drugs were developed with claims of fewer side effects and limited abuse potential. The data regarding this new group of drugs and its effect on the cardiovascular system is limited. We report a case of atomoxetine induced myocardial infarction (MI) in a young woman.

Original languageEnglish (US)
Pages (from-to)153-154
Number of pages2
JournalSouthern medical journal
Issue number2
StatePublished - Feb 2011
Externally publishedYes


  • atomoxetine
  • attention deficit hyperactivity syndrome
  • myocardial infarction

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Atomoxetine-induced myocardial infarction'. Together they form a unique fingerprint.

Cite this